App-Quantinova.ai

Real-world data (RWD) of the use of trifluridine/tipiracil hydrochloride (TFT) in patients with metastatic colorectal cancer: The Greater Manchester experience

A. Alchawaf - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Trifluridine and Tipiracil Hydrochloride

A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma: EMERALD-1

B. Sangro - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Bevacizumab

Systematic review and meta-analysis of the efficacy of chemotherapeutic regimens in advanced gallbladder cancer: Assessing current practice and treatment benefit

A. Azizi - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gallbladder cancer

N/A

Maintenance olaparib in patients aged ≥65 years with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial

H. Kindler - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic pancreatic adenocarcinoma

Olaparib

phase Ib/II, open-label, randomised evaluation of atezolizumab plus RO6874281 vs control in MORPHEUS–pancreatic ductal adenocarcinoma

V. Chung - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

Atezolizumab

Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo

A. El-Khoueiry - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Cabozantinib

Occupational physical activity and the risk of gastroesophageal reflux disease, Barrett’s oesophagus and oesophageal adenocarcinoma: A prospective cohort study in UK Biobank

S. Lam - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal reflux disease

N/A

Can we screen for pancreatic cancer? Identifying a sub-population of patients at high risk of subsequent diagnosis using machine learning techniques applied to primary care data

A. Malhotra - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

Baseline diffusion-weighted magnetic resonance imaging features to predict recurrence of anal squamous cell carcinoma following chemoradiotherapy

K. Owczarczyk - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Anal squamous cell carcinoma

N/A

Consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the TRIBE2 study

B. Borelli - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

PanCO: Updated results of an open-label, single-arm pilot study of OncoSil P-32 microparticles in unresectable locally advanced pancreatic adenocarcinoma (LAPC) with gemcitabine + nab-paclitaxel or FOLFIRINOX chemotherapy

P. Ross - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

Gemcitabine

Discordant prognostic significance of negative lymph node size in patients with oesophageal cancer treated with either surgery or neoadjuvant chemotherapy and surgery: Results from the MRC OE02 trial

M. Kloft - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

N/A

KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma

H. Yoon - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Pembrolizumab

Efficacy and safety of ripretinib as ≥4th-line therapy for patients with gastrointestinal stromal tumor following crossover from placebo: Analyses from INVICTUS

C. Serrano - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastrointestinal stromal tumor

Regorafenib

First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Long-term follow-up results from a phase 1/2 study

Z. Wainberg - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

Irinotecan

ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer

A. Grothey - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Binimetinib

Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC

A. Grothey - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Binimetinib

‘It’s not disgraceful to say you can’t cope’ – Understanding the caregivers’ perspective in care home placement for people with Parkinson’s

A. Hand - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

[11C]PK11195 PET Imaging Reveals Neuroinflammation in Dementia with Lewy Bodies: NIMROD Study

A. Surendranathan - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Lewy body dementia

N/A

[11C]PK11195 PET in Alzheimer’s disease and progressive supranuclear palsy: the NIMROD study

P. Vazquez Rodriguez - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Progressive supranuclear palsy

N/A

Filters

45280 Abstracts